New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
Rhea-AI Summary
Indivior (Nasdaq: INDV) released a cost impact model (March 31, 2026) estimating that monthly injectable buprenorphine (SUBLOCADE) could cut staff time and related costs for treating 100 incarcerated patients with opioid use disorder versus other MOUD options.
The model reported specific staff-hour reductions (318 vs methadone; 747 vs oral buprenorphine; 192 vs weekly extended-release buprenorphine; six vs extended-release naltrexone) and estimated monthly cost savings ranging from $23 to $22,148. The study excluded medication acquisition costs and was funded by Indivior.
AI-generated analysis. Not financial advice.
Positive
- 318 fewer staff hours vs methadone per 100 patients monthly
- 747 fewer staff hours vs oral buprenorphine per 100 patients monthly
- Estimated monthly cost savings up to $22,148 for 100 patients
Negative
- Study excluded medication acquisition costs, limiting total cost conclusions
- Study funded by Indivior, posing potential conflict of interest
- Estimated savings range widely from $23 to $22,148, limiting predictability
News Market Reaction – INDV
On the day this news was published, INDV gained 5.91%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
INDV slipped 0.66% while key peers showed mixed moves (e.g., HCM -0.69%, SUPN -1.06%, KNSA +0.24%). Only ALKS appeared in a momentum scan, moving up without news, suggesting today’s dynamics are stock-specific rather than a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | MOUD access survey | Positive | +1.2% | Survey showed major MOUD access gaps, underscoring unmet need for treatments. |
| Mar 12 | Convertible notes priced | Neutral | +0.8% | Upsized $450M 0.625% 2031 convertible notes with premium conversion price. |
| Mar 12 | Convertible notes proposed | Negative | -6.0% | Announced proposed $400M convertible notes with optional $60M upsizing. |
| Mar 11 | SUBLOCADE outcomes study | Positive | -1.5% | Real-world data showed $15,017 lower annual non-MOUD medical costs for adherent users. |
| Feb 26 | Q4/FY 2025 earnings | Positive | +0.2% | Reported record SUBLOCADE revenue, higher GAAP net income, and 2026 guidance. |
INDV has generally traded in line with fundamentally significant updates (earnings, financing), but MOUD-related research news has shown mixed and sometimes contrary price reactions.
Over the last six months, INDV has combined financial strengthening with growing evidence for SUBLOCADE’s value. Earnings on Feb 26, 2026 highlighted record SUBLOCADE revenues and higher adjusted EBITDA. In March, the company executed and priced 0.625% convertible notes, with generally aligned price reactions. Multiple March publications on MOUD access and SUBLOCADE’s cost and utilization benefits in various settings frame today’s correctional-facility staffing model as part of a sustained evidence-building campaign.
Market Pulse Summary
The stock moved +5.9% in the session following this news. A strong positive reaction aligns with INDV’s broader strategy of building evidence for SUBLOCADE’s real-world value. The new model suggests meaningful staffing and cost efficiencies in carceral settings while the stock trades above its $27.23 200‑day MA and about a quarter below its $38.00 52‑week high. Past research updates have sometimes produced mixed moves, so sustainability has depended on broader fundamentals and positioning.
Key Terms
extended-release buprenorphine medical
sublocade medical
medications for opioid use disorder medical
long-acting injectables medical
opioid use disorder medical
cost impact model technical
AI-generated analysis. Not financial advice.
- Model estimates SUBLOCADE® may reduce staff time and associated costs compared with other medications for opioid use disorder in jails and prisons
RICHMOND, Va., March 31, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (Nasdaq: INDV) today announced findings from a new cost impact model published in The Journal of Current Medical Research and Opinion, estimating that the use of extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, may reduce staff time and associated costs in jails and prisons compared with other medications for opioid use disorder (MOUD).
“Correctional facilities face ongoing staffing constraints as the need for MOUD continues to grow,” said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. “These findings highlight how monthly injectable buprenorphine can reduce dosing burden and staff involvement, enabling facilities to operate more efficiently while expanding access to evidence-based care.”
The model compared staff time requirements across four MOUD options including methadone, oral buprenorphine, extended-release buprenorphine, and extended-release naltrexone, estimating monthly staffing needs and costs for treating 100 incarcerated patients with OUD.
Using national mean wages and administration time estimates from literature, expert input, and manufacturer guidance, the model found:
- Reduced staff time: Monthly buprenorphine injections required fewer staff hours than other MOUD treatments—318 fewer staff hours vs. methadone; 747 fewer hours vs. oral buprenorphine; 192 hours fewer vs. weekly extended-release buprenorphine, and six hours fewer vs. extended-release naltrexone.
- Estimated cost savings: Reduced staff time translated to monthly cost savings ranging from
$23 t o$22,148 , with largest savings stemming from the elimination of daily observed dosing and patient escorts.
“Investing in more efficient MOUD delivery models can drive meaningful cost savings,” said Vanessa Procter, Executive Vice President of Corporate Affairs at Indivior. “Nearly half of U.S. jails and prisons cite staffing as a primary barrier to providing MOUD. LAIs can help expand access to evidence-based care while reducing operational burden, advancing shared public policy goals of improving health outcomes.”
Study limitations include the exclusion of medication acquisition costs and some administration times and escorting procedures were based on assumptions in the absence of available data.
Funded by Indivior, the study was conducted with Veradigm and researchers from the University of Kentucky College of Medicine. The full study findings are available here: Staffing Resource Use: Medications for Opioid Use Disorder Cost Impact Model in Carceral Facilities.
About SUBLOCADE®
SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII
INDICATION AND HIGHLIGHTED SAFETY INFORMATION
INDICATION
SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support.
HIGHLIGHTED SAFETY INFORMATION
WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY
- Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously.
- Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.
CONTRAINDICATIONS
Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE.
WARNINGS AND PRECAUTIONS
Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors.
Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE.
Risk of Serious Injection Site Reactions: Likelihood may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema, and pruritus with some involving abscess, ulceration, and necrosis.
Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy.
Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid.
Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately.
Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment.
Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE.
Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect.
ADVERSE REACTIONS
Adverse reactions commonly associated with SUBLOCADE (in ≥
For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit www.sublocade.com.
About Opioid Use Disorder (OUD)
Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions.
About Indivior
As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities – we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.
For Further Information
Investors:
Jason Thompson
Indivior Pharmaceuticals
Tel: 804-402-7123
E-mail: jason.thompson@indivior.com
Media:
Cassie France-Kelly
Indivior Pharmaceuticals
Tel: 804-594-0836
E-mail: Indiviormediacontacts@indivior.com
